GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis
Status:
Withdrawn
Trial end date:
2018-09-28
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of GSK2894512 cream for the topical
treatment of plaque psoriasis (psoriasis) with its vehicle cream. This is a randomized,
double-blind, vehicle-controlled, parallel-group, multicenter study in adults with psoriasis.
The aim of this study is to show superiority of GSK2894512 over vehicle by comparing their
response rates. The study will consist of 3 periods: up to 4 weeks screening, 12 weeks
blinded treatment, and 1 week post-treatment follow-up period. Subjects will apply randomized
study treatment to all psoriasis lesions once daily for 12 weeks. Subjects will be stratified
by Baseline physician global assessment (PGA) category (PGA score=2, PGA score >=3) at
randomization. Approximately 120 subjects will be randomized into the study of which 80 will
receive GSK2894512 1% cream and 40 will receive vehicle cream. Total duration of a subject's
participation in the study will be approximately for 14 to 17 weeks.